Health Care·Pharmaceuticals·$153.6B
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $0.58 | N/A | +3.76% |
| Revenue | N/A | N/A | N/A |
management commentary, guidance changes, and full analysis available with Pro.
| EPS | $0.58 | N/A | +3.76% |
| Revenue | N/A | N/A | N/A |
Tone: Cautiously Optimistic
Overall, management conveyed a sense of cautious optimism regarding the company's performance. They highlighted the importance of their ongoing projects.
Management expressed satisfaction with the EPS results despite not providing revenue figures.
They emphasized ongoing efforts in research and development.
Pfizer's earnings report shows a positive surprise in EPS, which contributed to a 1.66% increase in stock price. The lack of revenue data leaves some uncertainty, but management's optimistic tone suggests confidence in future performance. Investors may view the EPS beat as a sign of underlying strength in the company's operations.
AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.
No charge today · Auto-bills $8/mo after 7 days · Cancel anytime
SEAGATE TECHNOLOGY H
Oct 28, 2013